Search Results

CENTRAL Study of FlowCardia’s Crosser Initiated

February 9, 2010—FlowCardia, Inc. (Sunnyvale, CA) announced the initiation of enrollment for the CENTRAL (Crosser Enters the Right Arterial Lumen) study of the company's Crosser recanalization catheter for treating chronic total occlusions (CTOs).

CENTRAL CTO Study of FlowCardia's Crosser Begins

February 9, 2010—FlowCardia, Inc. (Sunnyvale, CA) announced the initiation of enrollment for the CENTRAL (Crosser Enters the Right Arterial Lumen) study of the company's Crosser recanalization catheter for treating chronic total occlusions (CTOs).

FDA Clears Avinger's Wildcat Catheter for CTO Treatment

August 16, 2011—Avinger, Inc. (Redwood City, CA) has received 510(k) clearance from the US Food and Drug Administration to market its Wildcat catheter for crossing chronic total occlusions (CTOs) to allow treatment via balloon angioplasty, stent, or atherectomy for peripheral artery disease.

AtheroMed Begins EASE Trial of Phoenix Atherectomy Catheter

September 2, 2010—AtheroMed, Inc. (Menlo Park, CA) announced the start of enrollment in the EASE (Endovascular Atherectomy Safety and Effectiveness) study to evaluate the safety and effectiveness of the Phoenix atherectomy catheter for treating peripheral arterial disease.

Ra Medical Announces Progress of the Next-Generation DABRA Excimer Laser System

June 29, 2021—Ra Medical Systems, Inc. announced that enrollment in the pivotal atherectomy clinical trial with its DABRA excimer laser system is now at 62 patients, including 42 patients enrolled since the beginning of 2021.

LEOPARD to Compare Endologix AFX System to Other Commercially Available EVAR Devices

September 29, 2014—Endologix, Inc. announced that it will conduct a prospective, randomized clinical trial to compare outcomes in endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs). The company says the LEOPARD trial (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) has been designed to provide an unbiased assessment of commercially available EVAR devices.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

April 8, 2024—Synchron, a neurotechnology company developing an endovascular brain-computer interface (BCI) to restore functionality in patients with motor impairment, announced the launch of a community-centered BCI registry.